Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of diseas... Read more
BioAnalysis, LLC
1 follower
CSL
85 followers
Telix Pharma
8 followers
Vaxcyte
5 followers
Zura Bio
1 follower
Tango Therapeutics
3 followers
Capricor Therapeutics
2 followers
MSD Australia & New Zealand
1 follower
Ascidian Therapeutics
2 followers
Gloucester Marine Genomics Institute
1 follower
Hound Labs
1 follower
The ABC
17 followers